Read by QxMD icon Read

statins with time of dosing

Daniel R Morales, Jim Slattery, Alexandra Pacurariu, Luis Pinheiro, Patricia McGettigan, Xavier Kurz
BACKGROUND AND OBJECTIVE: Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. METHODS: The UK Health Improvement Network primary care database was used to perform a nested case-control study measuring the association between fluoroquinolone exposure and tendon rupture. Adults with tendon rupture were matched on age, sex, general practice and calendar time to four controls selected from a cohort prescribed systemic fluoroquinolone or co-amoxiclav antibiotics...
November 21, 2018: Clinical Drug Investigation
Andrew D Spence, John Busby, Carmel M Hughes, Brian T Johnston, Helen G Coleman, Chris R Cardwell
PURPOSE: Preclinical studies show statins inhibit pathways involved in gastric cancer progression, with observational studies demonstrating reduced gastric cancer risk in statin users. However, few studies have investigated statin use and survival in gastric cancer. We investigated statin use and survival in two large population-based gastric cancer cohorts. METHODS: Patients diagnosed with gastric cancer from 1998 to 2012 were identified from English and Scottish cancer registries...
November 20, 2018: Pharmacoepidemiology and Drug Safety
Zhiwei Liu, Rotana Alsaggaf, Katherine A McGlynn, Lesley A Anderson, Huei-Ting Tsai, Bin Zhu, Yue Zhu, Sam M Mbulaiteye, Shahinaz M Gadalla, Jill Koshiol
OBJECTIVE: To evaluate the association between statin use and risk of biliary tract cancers (BTC). DESIGN: This is a nested case-control study conducted in the UK Clinical Practice Research Datalink. We included cases diagnosed with incident primary BTCs, including cancers of the gall bladder, bile duct (ie, both intrahepatic and extrahepatic cholangiocarcinoma), ampulla of Vater and mixed type, between 1990 and 2017. For each case, we selected five controls who did not develop BTCs at the time of case diagnosis, matched by sex, year of birth, calendar time and years of enrolment in the general practice using incidence density sampling...
November 17, 2018: Gut
Michael Lawrenz F Co, Arianne Clare Agdamag, Mita Zahra Co, Martin Hertl, Burhan Mohamedali
Statin use in patients listed for in kidney transplant is believed to be beneficial. However, the optimum statin dose for improved survival in this high-risk population is unknown. Our study aimed to determine the impact of prekidney transplant statin dosage on survival postkidney transplant. In this retrospective cohort study, we enrolled patients who underwent kidney transplant from January 2005 to September 2015 at Rush University Medical. Data on the statin use and intensity used before kidney transplant were obtained...
October 18, 2018: American Journal of Cardiology
Dirk Essers, Martina Schäublin, Gerd A Kullak-Ublick, Stefan Weiler
PURPOSE: Statins represent an effective treatment for hyperlipidaemia. Immune-mediated necrotising myopathy (IMNM), a form of statin myopathy, has recently been described, and is characterized by elevated creatine kinase, presence of antibodies against HMG-CoA and no improvement after drug discontinuation, even with immunosuppressive treatment. Information on IMNM is mainly from case reports and small case series. Therefore, all reported cases of IMNM in VigiBase, the WHO global database of individual case safety reports (ICSRs) including the underlying reporting patterns, were analysed to characterize more detailed this adverse drug reaction...
November 15, 2018: European Journal of Clinical Pharmacology
Lucyna Matusewicz, Joanna Podkalicka, Aleksander F Sikorski
Lipophilic statins are promising candidates for breast cancer treatment. However, anticancer therapy requires much higher doses of statins than can be delivered orally, and such high doses are known to exert more adverse effects. The main objective of our study was to design a targeted, therapeutic liposomal carrier of simvastatin characterised by high stability and specificity towards breast cancer cells. We chose SKBR3, the cell line that showed the highest sensitivity for simvastatin and liposomal simvastatin treatment...
November 1, 2018: Cancers
Giuseppe Di Stolfo
BACKGROUND: Carotid stenting stimulates intimal proliferation through platelet and stem cell activation. OBJECTIVE: The aim of this study is to evaluate whether the administration before or after carotid stenting of clopidogrel loading dose may play a role on circulating endothelial progenitor cells, stromal cell-derived factor-1α (SDF-1α) and neointimal hyperplasia. METHODS: We recruited 13 patients (aged 74.52±7.23) with indication of carotid revascularization and in therapy with salicylic acid and statin...
September 29, 2019: Clinical Hemorheology and Microcirculation
Ning Yang, Bo Dong, Jinyu Yang, Yang Li, Lu Kou, Yue Liu, Qin Qin
BACKGROUND: Restenosis after percutaneous coronary intervention in coronary heart disease remains an unsolved problem. Clusterin (CLU) (or Apolipoprotein [Apo] J) levels have been reported to be elevated during the progression of postangioplasty restenosis and atherosclerosis. However, its role in neointimal hyperplasia is still controversial. OBJECTIVE: To elucidate the role Apo J in neointimal hyperplasia in a rat carotid artery model in vivo with or without rosuvastatin administration...
October 2018: Arquivos Brasileiros de Cardiologia
Branislav Vohnout, Ľubomíra Fábryová, Alexander Klabník, Michaela Kadurová, Karin Bálinth, Miriam Kozárová, Ingrid Bugáňová, Jana Sirotiaková, Katarína Rašlová
BACKGROUND AND AIMS: Maximal doses of potent statins are the cornerstone of treatment of familial hypercholesterolemia (FH). Despite this, a substantial proportion of FH patients are either under-treated or not treated at all. The aim of this work was to evaluate, in a retrospective study, the treatment of FH patients, the proportion of FH patients reaching low-density lipoprotein cholesterol (LDL-C) goals, and reasons for not reaching LDL-C goals, in 8 lipid clinics in Slovakia dealing with FH patients...
October 2018: Atherosclerosis
Renato D Lopes, Pedro G M de Barros E Silva, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lilian Mazza Barbosa, Lucas Petri Damiani, Renato Hideo Nakagawa Santos, Ligia Nasi Laranjeira, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, John H Alexander, Christopher B Granger, Otavio Berwanger
Importance: Loading doses of atorvastatin did not show reduction on clinical outcomes in the overall population of patients with acute coronary syndrome (ACS) enrolled in the Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) trial, but a potential benefit was identified in patients who subsequently underwent percutaneous coronary intervention (PCI). Objectives: To determine whether periprocedural loading doses of atorvastatin are associated with decreased 30-day major adverse cardiovascular events (MACE) in patients with ACS undergoing PCI according to type of ACS and timing of atorvastatin administration before PCI...
November 1, 2018: JAMA Cardiology
Tao-Min Huang, Vin-Cent Wu, Yu-Feng Lin, Jian-Jhong Wang, Chih-Chung Shiao, Likwang Chen, Shih-Chieh Jeff Chueh, Eric Chueh, Shao-Yu Yang, Tai-Shuan Lai, Shuei-Liong Lin, Tzong-Shinn Chu, Kwan-Dun Wu
Although statin treatment is recommended for patients with chronic kidney disease (CKD) stages I⁻IV, its potential benefits have not been reported in advanced CKD patients. Non-diabetic patients with advanced CKD (pre-dialysis patients, estimated glomerular filtration rate <15 mL/min/1.73 m²) were enrolled from a National Health Insurance Research Database with a population of 23 million. Statin users and non-users were matched using propensity scoring and analyzed using Cox proportional hazards models, taking mortality as a competing risk with subsequent end-stage renal disease (ESRD) and statin doses as time-dependent variables...
September 17, 2018: Journal of Clinical Medicine
Mohamed Sobhy, Adel El Etriby, Amany El Nashar, Sameh Wajih, Martin Horack, Philippe Brudi, Dominik Lautsch, Baishali Ambegaonkar, Ami Vyas, Anselm K Gitt
Background: Effective management of hyperlipidemia is of utmost importance for prevention of recurring cardiovascular events after an acute coronary syndrome (ACS). Indeed, guidelines recommend a low-density lipoprotein cholesterol (LDL-C) level of <70 mg/dL for such patients. The Dyslipidemia International Study II (DYSIS II) - Egypt was initiated in order to quantify the prevalence and extent of hyperlipidemia in patients presenting with an ACS in Egypt. Methods: In this prospective, observational study, we documented patients presenting with an ACS at either of two participating centers in Egypt between November 2013 and September 2014...
September 2018: The Egyptian heart journal: (EHJ): official bulletin of the Egyptian Society of Cardiology
Anselm K Gitt, Johannes Rieber, Rainer Hambrecht, Johannes Brachmann, Kristof Graf, Martin Horack, Barbara Karmann, Ami Vyas, Dominik Lautsch, Baishali Ambegaonkar, Philippe Brudi
OBJECTIVE: To document utilization of lipid-lowering therapy, attainment of low-density lipoprotein cholesterol target values, and cardiovascular outcomes in patients hospitalized for acute coronary syndrome in Germany. METHODS: The Dyslipidemia International Study II was a multicenter, observational study of the prevalence of dyslipidemia and lipid target value attainment in patients surviving any acute coronary syndrome event. Among patients on lipid-lowering therapy for ≥3 months, use of lipid-lowering therapy and lipid profiles were assessed at admission and again at 120 ± 15 days after admission (the follow-up time point)...
September 3, 2018: Wiener Klinische Wochenschrift
Ramsha Riaz, Aleena Zehra Merchant, Muhammad Salman Ul Haq, Syed Ali Raza Nasir, Yusra Rizvi, Jehanzeb Ahmed Khan, Sara Mohiuddin Zakaria, Hassaan Jawed, Khizar Hamid, Noor-Ul-Ain Zehra, Madiha Ahmed, Hussain Asif Ali, Kaneez Fatima
OBJECTIVE: Statins are widely used drugs, known to cause myalgia, leading to high discontinuation rates. The objective of our study was to determine the frequency of myalgia in patients on everyday-dose (EDD) regimen with those on alternate-day dose (ADD) regimen. METHODS: This cross sectional study was conducted in a tertiary care hospital of Pakistan. A sample size of 400 patients between the age of 40-70 years, taking simvastatin 40mg for at least 6 months or more were selected...
July 2018: Indian Heart Journal
Kaku Nakano, Tetsuya Matoba, Jun-Ichiro Koga, Yushi Kashihara, Masato Fukae, Ichiro Ieiri, Masanari Shiramoto, Shin Irie, Junji Kishimoto, Koji Todaka, Kensuke Egashira
Pulmonary hypertension (PH) is a disease with poor prognosis, caused by the obstruction/stenosis of small pulmonary arteries. Statin is known to have vasodilating and anti-inflammatory property and is considered to be a candidate of therapeutic agents for the treatment of PH, but its efficacy has not been verified in clinical trials. We have formulated pitavastatin incorporating nanoparticles composed of poly (lactic-co-glycolic acid) (NK-104-NP) to improve drug delivery to the pulmonary arteries and evaluated their safety and pharmacokinetics in healthy volunteers...
September 26, 2018: International Heart Journal
Yewon Choi, SeungHwan Lee, In-Jin Jang, Kyung-Sang Yu
Introduction: Major cardiovascular risk factors, including hypertension and dyslipidemia, are often comorbidities, frequently leading to concurrent prescription of angiotensin receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). The study's objective was to evaluate the effect of coadministration of fimasartan and atorvastatin on their pharmacokinetics (PKs). Subjects and methods: In a randomized, open-label, three-period, six-sequence, crossover, multiple-dose study, 36 healthy subjects received 120 mg fimasartan, 40 mg atorvastatin, or both (based on their assigned sequence) once daily for 7 days in each period, with a 7-day washout between periods...
2018: Drug Design, Development and Therapy
Tamara R Nikolic Turnic, Vladimir Lj Jakovljevic, Dragan M Djuric, Nevena S Jeremic, Jovana N Jeremic, Isidora M Milosavljevic, Ivan M Srejovic, Dragica V Selakovic, Vladimir I Zivkovic
The aim of this study was to assess the impact of atorvastatin and simvastatin on myocardial contractility during the different degrees of hyperhomocysteinemia (HHcy) in rats. Study was conducted on adult male Wistar albino rats (n = 90; 4 weeks old; 100 ± 15 g body mass) in which HHcy was achieved by dietary manipulation. Animals were exposed to pharmacology treatment with atorvastatin in dose of 3 mg/kg per day i.p. or simvastatin in dose of 5 mg/kg per day i.p. at the same time every day, according to equivalent therapeutic doses of these statins (10 mg atorvastatin = 20 mg simvastatin)...
October 2018: Canadian Journal of Physiology and Pharmacology
Florine Tissier, Firas Farhat, Clothilde Philouze, Jean-Claude Desfontis, Romain Didier, Martine Gilard, M Yassine Mallem, Jacques Mansourati, Christine Moisan, Karine Pichavant-Rafini, Michael Theron, Aline Amérand
Statins are currently used in prevention of cardiovascular diseases in high-risk populations, and could be considered in primary prevention. However, few studies are available on the long-term effects of low doses of statins, especially on mitochondrial function and reactive oxygen species (ROS) metabolism at cardiac level. This study aimed to determine potential effects of a long-term atorvastatin treatment, at low-dose concentration, on the myocardium mitochondrial respiration. Thirty-four Watanabe rabbits were treated or not with atorvastatin (2...
November 2018: Canadian Journal of Physiology and Pharmacology
Junyu Zhao, Chunmei Xu, Jinming Yao, Changzhen Yu, Lin Liao, Jianjun Dong
BACKGROUND/AIMS: Experimental studies have reported the antineoplastic effects of statins in thyroid carcinoma; however, observational studies suggested that statins might increase the risk of thyroid carcinoma. Therefore, this study evaluated the antineoplastic effects of statins in both in vitro studies and animal models, as well as the epidemiological evidence. METHODS: Databases-PubMed, Cochrane Library, SinoMed, CNKI, Wanfang, and clinical trial registries- were searched...
2018: Cellular Physiology and Biochemistry
Gaetano M De Ferrari, Gian P Perna, Antonino Nicosia, Luigina Guasti, Gavino Casu, Claudio Cuccia, Francesca Picco, Caterina Strazzella, Rossana Totaro, Stefania Cercone, Laura Canullo, Martin Horack, Dominik Lautsch, Anselm K Gitt, Matteo Di Biase
AIMS: The analysis evaluated the contemporary percentage of patients with established coronary heart disease (CHD) reaching the European guidelines recommended LDL-cholesterol (LDL-C) levels of less than 70 mg/dl and the threshold required for proprotein convertase subtlisin/kexin type 9 reimbursement in Italy (100 mg/dl). It also assessed how these percentages would change in case of diffuse use of ezetimibe. METHODS: The Dyslipidemia International Study II enrolled CHD patients aged at least 18 either on lipid-lowering therapy (LLT) for at least 3 months or not on LLT at the time of the lipid profile...
September 2018: Journal of Cardiovascular Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"